Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4300829 | 0.73 | — | — | |
| SCHEMBL15558497 | 0.66 | TRPA1 (0.33) | TSHRGFER | |
| SCHEMBL9475347 | 0.60 | CHEK1 (0.50) | CHEK1CYP1A2CYP2D6CYP2C9L3MBTL1 | |
| SCHEMBL4296233 | 0.57 | CHEK1 (0.47) | CHEK1MAPTLMNAMEN1KMT2A | |
| SCHEMBL20312981 | 0.57 | KMT2A (0.42) | CHEK1MAPTLMNAL3MBTL1MEN1 | |
| SCHEMBL31514754 | 0.57 | KMT2A (0.42) | CHEK1MAPTLMNAL3MBTL1MEN1 | |
| SCHEMBL29417721 | 0.57 | PTGDR2 (0.48) | CHEK1MAPTLMNACYP1A2CYP2C9 | |
| SCHEMBL795719 | 0.57 | PTGDR2 (0.48) | CHEK1MAPTLMNACYP1A2CYP2C9 | |
| SCHEMBL135165 | 0.56 | PTGDR2 (0.49) | MAPTLMNAMEN1KMT2A | |
| SCHEMBL507839 | 0.56 | PYCR1 (0.46) | CYP1A2CYP2C9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | CHEK1, CHEK2, CDKN1A | CHEK1 1/4885MAPT 3674/4885LMNA 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.